Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrzej Jakubowski is active.

Publication


Featured researches published by Andrzej Jakubowski.


Circulation | 2002

S-Nitroso Human Serum Albumin Treatment Reduces Ischemia/Reperfusion Injury in Skeletal Muscle via Nitric Oxide Release

Seth Hallström; Harald Gasser; Christoph Neumayer; Alexander Fügl; J. Nanobashvili; Andrzej Jakubowski; Ihor Huk; Günther Schlag; Tadeusz Malinski

Background—Peroxynitrite generated from nitric oxide (NO) and superoxide (O2−) contributes to ischemia/reperfusion (I/R) injury. Feedback inhibition of endothelial NO synthase by NO may inhibit O2− production generated also by endothelial NO synthase at diminished local l-arginine concentrations accompanying I/R. Methods and Results—During hindlimb I/R (2.5 hours/2 hours), in vivo NO was monitored continuously (porphyrinic sensor), and high-energy phosphates, reduced and oxidized glutathione (chromatography), and I/R injury were measured intermittently. Rabbits receiving human serum albumin (HSA) (controls) were compared with those receiving S-nitroso human serum albumin (S-NO-HSA) beginning 30 minutes before reperfusion for 1 hour or 30 minutes before ischemia for 3.5 hours (0.1 &mgr;mol · kg−1 · h− 1). The onset of ischemia led to a rapid increase of NO from its basal level (50±12 nmol/L) to 120±20 and 220±15 nmol/L in the control and S-NO-HSA–treated groups, respectively. In control animals, NO dropped below basal levels at the end of ischemia and to undetectable levels (<1 nmol/L) during reperfusion. In S-NO-HSA–treated animals, maximal NO levels never decreased below basal concentration and on reperfusion were 100±15 nmol/L (S-NO-HSA preischemia group, 175±15 nmol/L). NO supplementation by S-NO-HSA led to partial and in the preischemia group to total preservation of high-energy phosphates and glutathione status in reperfused muscle (eg, preischemia groups: ATP, 30.23±5.02 &mgr;mol/g versus control, 15.75±4.33 &mgr;mol/g, P <0.0005; % oxidized glutathione, 4.49± 1.87% versus control, 22.84±6.39%, P <0.0001). S-NO-HSA treatment in all groups led to protection from vasoconstriction and reduced edema formation after reperfusion (eg, preischemia groups: interfiber area, 12.94±1.36% versus control, 27.83±1.95%, P < 0.00001). Conclusions—Long-lasting release of NO by S-NO-HSA provides significant protection of skeletal muscle from I/R injury.


Pharmacological Reports | 2010

Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse

Magdalena Sternak; Tamara I. Khomich; Andrzej Jakubowski; Malgorzata Szafarz; Wojciech Szczepański; Magdalena Białas; Marta Stojak; Joanna Szymura-Oleksiak; Stefan Chlopicki

Nicotinamide N-methyltransferase (NNMT), which converts nicotinamide (NA) to 1-methylnicotinamide (MNA), is up-regulated in the cirrhotic liver. Because MNA displays PGI(2)-dependent anti-inflammatory effects, the up-regulation of NNMT may play a regulatory role in liver inflammation. In the present work, we analyzed changes in NNMT activity in the liver and concomitant changes in the concentration of endogenous MNA in plasma in T-cell dependent hepatitis induced by concanavalin A (ConA) in BALB/c mice. Furthermore, we tested whether exogenous MNA possessed a protective effect against ConA-induced hepatitis. Development of liver injury induced by ConA (10 mg/kg, iv) was characterized by measurements of plasma concentration of alanine aminotransaminase (ALT), inflammatory cytokines (INF gamma and TNFalpha) and by histopathological examination. ConA-induced hepatitis was characterized by an early activation of inflammatory cytokines (IFN gamma; from below 0.05 ng/ml to 23.72 +/- 8.80 ng/ml; TNFalpha;from 0.07 +/- 0.01 ng/ml to 0.71 +/- 0.12 ng/ml, 2 h after ConA), an elevation of ALT (from 40.65 +/- 3.2 U/l to 5,092.20 +/- 1,129.05 U/l, 8 h after ConA) and by morphological signs of severe liver inflammation and injury (24 h after ConA). In mice injected with ConA, NNMT activity in the liver was up-regulated approximately 2-fold to 3-fold, 8-24 h after ConA injection. The concentration of MNA and its metabolites (Met-2PY and Met-4PY) in plasma were elevated approximately 2-fold 8 h after ConA injection. Exogenous MNA (100 mg/kg, iv) diminished ConA-induced liver injury, and this effect was reversed by an antagonist of the prostacyclin receptor, RO 3244794 (10 mg/kg, po). In conclusion, the present study demonstrated that hepatic NNMT activity and MNA concentration in plasma significantly increased during the progression of ConA-induced hepatitis in mice. This response may play a hepatoprotective role compatible with the PGI(2)-releasing properties of MNA.


Journal of Inorganic Biochemistry | 1998

Cyanonitrosylmetallates as potential NO-donors

Janusz Oszajca; Grażyna Stochel; Ewa Wasielewska; Zofia Stasicka; Gryglewski Rj; Andrzej Jakubowski; Katarzyna Cieślik

The [M(CN)xNOy]n- complexes (where M = Cr(I), Mn(I), Mn(II), Fe(I), Fe(II), Fe(III)) were studied as potential NO-donors using both pharmacological and theoretical semi-empirical methods. Only iron complexes appeared to be pharmacologically active. The quantum chemical calculations indicated that these complexes have the highest predisposition to undergo a nucleophilic attack followed by the NO+ release. The results allowed us to interpret the metabolism of the [M(CN)xNOy]n- complexes in terms of the NO(+)-donation.


International Immunopharmacology | 2016

1-Methylnicotinamide protects against liver injury induced by concanavalin A via a prostacyclin-dependent mechanism: A possible involvement of IL-4 and TNF-α

Andrzej Jakubowski; Magdalena Sternak; Konrad Jabłoński; Marta Ciszek-Lenda; Janusz Marcinkiewicz; Stefan Chlopicki

We have recently demonstrated that concanavalin A (Con A)-induced hepatitis is associated with the release of endogenous 1-methylnicotinamide (MNA). Here we study the mechanism by which exogenous MNA alleviates Con A-induced liver inflammation and injury in vivo. The involvement of prostacyclin (PGI2) in hepatoprotective action of MNA (30-100 mg kg(-1); i.v.) was studied by the use of IP receptor antagonist RO3244794 (10 mg kg(-1); p.o.) given prior to Con A (5-20 mg kg(-1); i.v.). Liver damage was assessed by measurements of: liver specific transaminases in plasma (alanine aminotransferase; aspartate aminotransferase); cytokines release (IL-4, IFN-γ and TNF-α); liver histopathology; and 24h survival rates. Additionally, the effect of a stable analog of prostacyclin (carbaprostacyclin) on IL-4, IFN-γ and TNF-α production by isolated spleen lymphocytes in response to Con A was analyzed. MNA diminished Con A-induced rise in liver specific transaminases, alleviated histopathological injury and improved 24h survival rates, the latter effect in a degree comparable with the pretreatment of animals with dexamethasone (0.5 mg kg(-1); i.p.). MNA inhibited also a rise in IL-4 and TNF-α concentration in plasma measured 2 h after Con A administration, while IFN-γ was less affected. The effects of MNA were reversed by pretreatment with IP antagonist RO3244794. In isolated spleen lymphocytes, carbaprostacyclin profoundly decreased production of IL-4, the effect on TNF-α was modest with no effect on IFN-γ production. In conclusion, MNA attenuated Con A-induced hepatitis by a prostacyclin-dependent mechanism involving the inhibition of lymphocytes-derived IL-4 and the inhibition of Kuppfer-cells derived TNF-α.


International Immunopharmacology | 2015

Differential involvement of IL-6 in the early and late phase of 1-methylnicotinamide (MNA) release in Concanavalin A-induced hepatitis

Magdalena Sternak; Andrzej Jakubowski; Elżbieta Czarnowska; Ewa M. Slominska; Ryszard T. Smolenski; Malgorzata Szafarz; Maria Walczak; Barbara Sitek; Tomasz Wojcik; Agnieszka Jasztal; Karol A. Kamiński; Stefan Chlopicki

Exogenous 1-methylnicotinamide (MNA) displays anti-inflammatory activity. The aim of this work was to characterize the profile of release of endogenous MNA during the initiation and progression of murine hepatitis induced by Concanavalin A (ConA). In particular we aimed to clarify the role of interleukin-6 (IL-6) as well as the energy state of hepatocytes in MNA release in early and late phases of ConA-induced hepatitis in mice. Hepatitis was induced by ConA in IL-6(+/+) and IL-6(-/-) mice, and various parameters of liver inflammation and injury, as well as the energy state of hepatocytes, were analysed in relation to MNA release. The decrease in ATP/ADP and NADH/NAD ratios, cytokine release (IL-6, IFN-ɤ), acute phase response (e.g. haptoglobin) and liver injury (alanine aminotransaminase, ALT) were all blunted in ConA-induced hepatitis in IL-6(-/-) mice as compared to IL-6(+/+) mice. The release of MNA in response to Con A was also significantly blunted in IL-6(-/-) mice as compared to IL-6(+/+) mice in the early stage of ConA-induced hepatitis. In turn, nicotinamide N-methyltransferase (NNMT) and aldehyde oxidase (AO) activities were blunted in the liver and MNA plasma concentration was elevated to similar degree in the late stage after Concanavalin A in IL-6(+/+) and IL-6(-/-) mice. In conclusion, we demonstrated that in ConA-induced hepatitis, early, but not late MNA release was IL-6-dependent. Our results suggest that in the initiation and early hepatitis, MNA release is linked to the energy deficit/impaired redox status in hepatocytes, while in a later phase, MNA release is rather linked to the systemic inflammation.


European Journal of Pharmacology | 2008

Anti-inflammatory effect of 1-methylnicotinamide in contact hypersensitivity to oxazolone in mice; involvement of prostacyclin

Krzysztof Bryniarski; Rafał Biedroń; Andrzej Jakubowski; Stefan Chlopicki; Janusz Marcinkiewicz


Prostaglandins Leukotrienes and Essential Fatty Acids | 2005

Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart

Andrzej Jakubowski; Stefan Chlopicki; Rafał Olszanecki; Jawień J; Magdalena Lomnicka; Dupin Jp; Gryglewski Rj


Liebigs Annalen | 1996

Synthesis and Properties of 2-Carboxyalkyl-1,2-benzisoselenazol-3(2H)-ones and Related Organoselenium Compounds as Nitric Oxide Synthase Inhibitors and Cytokine Inducers

Jacek Mlochowski; Leszek Juchniewicz; Krystian Kloc; Gryglewski Rj; Andrzej Jakubowski; Anna D. Inglot


Naunyn-schmiedebergs Archives of Pharmacology | 2009

S-nitroso human serum albumin given after LPS challenge reduces acute lung injury and prolongs survival in a rat model of endotoxemia

Andrzej Jakubowski; N. Maksimovich; R. Olszanecki; A. Gebska; Harald Gasser; Bruno K. Podesser; Seth Hallström; Stefan Chlopicki


Physiological Research | 1996

ISCHAEMIC CARDIAC HYPERAEMIA : ROLE OF NITRIC OXIDE AND OTHER MEDIATORS

Gryglewski Rj; Stefan Chlopicki; Niezabitowski P; Andrzej Jakubowski; Magdalena Lomnicka

Collaboration


Dive into the Andrzej Jakubowski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Seth Hallström

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Janusz Marcinkiewicz

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Malgorzata Szafarz

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Maria Walczak

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Bruno K. Podesser

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Harald Gasser

Medical University of Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge